Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Laban

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
International Journal of Molecular Sciences|August 23, 2020
Peripheral Cytokine Levels Differ by HPV Status and Change Treatment-Dependently in Patients with Head and Neck Squamous Cell CarcinomaDaphne Mytilineos, Jasmin Ezić, Adrian von Witzleben, et al.
International Journal of Cancer|December 18, 2019
Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cellsMax Wilkat, Hanna Bast, Robert Drees, et al.
International Journal of Cancer|December 18, 2020
Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC)Adrian von Witzleben, Adrian Fehn, Ayla Grages, et al.
Translational Oncology|April 17, 2026
CD3 and PD-L1 tissue expression have synergistic value in head and neck squamous cell carcinoma prognosisAdrian V Witzleben, Romain Remark, Christian Idel, et al.
Cancers|March 6, 2021
Increasing Mean Age of Head and Neck Cancer Patients at a German Tertiary Referral CenterJulius M Vahl, Marlene C Wigand, Michael Denkinger, et al.
Medcomm|January 16, 2026
Newly Identified Transcriptomic Biomarkers and Gene Signature of Pathological Complete Response to Induction Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaJian-Guo Zhou, Markus Eckstein, Haitao Wang, et al.
Oncotarget|February 2, 2017
MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapySimon Laban, Gregor Giebel, Niklas Klümper, et al.
Cancer Research|December 30, 2016
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> PolymorphismFriederike Braig, Malte Kriegs, Minna Voigtlaender, et al.
Cancers|April 30, 2021
Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck CancerSabine Semrau, Antoniu-Oreste Gostian, Maximilian Traxdorf, et al.
Journal for Immunotherapy of Cancer|October 7, 2020
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8Markus Hecht, Antoniu Oreste Gostian, Markus Eckstein, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
International Journal of Molecular Sciences|August 23, 2020
Peripheral Cytokine Levels Differ by HPV Status and Change Treatment-Dependently in Patients with Head and Neck Squamous Cell CarcinomaDaphne Mytilineos, Jasmin Ezić, Adrian von Witzleben, et al.
International Journal of Cancer|December 18, 2019
Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cellsMax Wilkat, Hanna Bast, Robert Drees, et al.
International Journal of Cancer|December 18, 2020
Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC)Adrian von Witzleben, Adrian Fehn, Ayla Grages, et al.
Translational Oncology|April 17, 2026
CD3 and PD-L1 tissue expression have synergistic value in head and neck squamous cell carcinoma prognosisAdrian V Witzleben, Romain Remark, Christian Idel, et al.
Cancers|March 6, 2021
Increasing Mean Age of Head and Neck Cancer Patients at a German Tertiary Referral CenterJulius M Vahl, Marlene C Wigand, Michael Denkinger, et al.
Medcomm|January 16, 2026
Newly Identified Transcriptomic Biomarkers and Gene Signature of Pathological Complete Response to Induction Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaJian-Guo Zhou, Markus Eckstein, Haitao Wang, et al.
Oncotarget|February 2, 2017
MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapySimon Laban, Gregor Giebel, Niklas Klümper, et al.
Cancer Research|December 30, 2016
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> PolymorphismFriederike Braig, Malte Kriegs, Minna Voigtlaender, et al.
Cancers|April 30, 2021
Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck CancerSabine Semrau, Antoniu-Oreste Gostian, Maximilian Traxdorf, et al.
Journal for Immunotherapy of Cancer|October 7, 2020
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8Markus Hecht, Antoniu Oreste Gostian, Markus Eckstein, et al.
Pageof 10